<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02861404</url>
  </required_header>
  <id_info>
    <org_study_id>BIOVRAIE</org_study_id>
    <nct_id>NCT02861404</nct_id>
  </id_info>
  <brief_title>Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment</brief_title>
  <acronym>BIOVRAIE</acronym>
  <official_title>Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective of the study is the evaluation of the role of Human Papilloma Virus
      (HPV) in plantar warts (prevalence, genotype), resistant or not, treated or not, cured or
      not. This epidemiological study is an ancillary study of the prospective, randomized
      controlled, clinical study VRAIE (sponsor: APHP) comparing 5 usual strategies in the
      management of plantar warts.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of HPV viral DNA on samples</measure>
    <time_frame>up to Day 90</time_frame>
    <description>research of positive HPV status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of viral genotypes</measure>
    <time_frame>up to Day 90</time_frame>
    <description>number of samples containing one or more viral type (type 1, 2, 4 or mix)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission defined</measure>
    <time_frame>up to Day 90</time_frame>
    <description>complete remission of wards confirmed by the physician, no later than day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral remission for patients with wards resistant to treatments</measure>
    <time_frame>up to Day 90</time_frame>
    <description>viral status modification from negative to positive between day 0 and day 30, day 60 or no more than day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical relapse</measure>
    <time_frame>21 months</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">406</enrollment>
  <condition>Plantar Warts</condition>
  <arm_group>
    <arm_group_label>Salicylate ointment</arm_group_label>
    <description>patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <description>patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Fluoro-Uracil</arm_group_label>
    <description>patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryotherapy</arm_group_label>
    <description>patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <description>patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>skin flakes collection</intervention_name>
    <description>viral status assessment of skin flakes</description>
    <arm_group_label>Salicylate ointment</arm_group_label>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_label>5-Fluoro-Uracil</arm_group_label>
    <arm_group_label>Cryotherapy</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        2000 skin flakes to be collected from patients included in VRAIE study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient aged 18 years or more.

          -  Clinical evaluation

          -  Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10
             cm, whether previously treated or not

          -  In treated patients, all potentially active treatment on warts since at least one
             month should be stopped.

          -  Effective contraception for women of childbearing age

          -  Immunocompetent patients

          -  Patient with one or more warts on soles and board feet.

               -  MYRMECIE : rounded warts, deep, covered with a stratum corneum more or less
                  thick; after stripping, appear black points, very specific; often painful to
                  pressure. They are lonely, single or not. They could regroup galley thick. The
                  stripping can them to individualize.

               -  Mosaic : plate small warts, superficial, often sitting on the heel or Forefoot.
                  Little painful, they are often ignored by the patients when they appear

          -  Patient affiliated to the French social security.viral

        Exclusion Criteria:

          -  Patient suspected to be immunocompromised

          -  Patient aged under 18 years

          -  Patient refusing to sign the consent

          -  Pregnant or lactating women

          -  Plantar calluses

          -  Known hypersensitivity to imiquimod (Aldara®) or any excipients of the cream
             (isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, paraffin,
             polysorbate 60, sorbitan stearate, glycerol, methyl hydroxybenzoate, propyl
             hydroxybenzoate, xanthan gum, purified water)

          -  Known hypersensitivity to 5 fluoro-uracil (Efudix®) or any excipients of gel (stearyl
             alcohol, Vaseline, polysorbate 60, propyleneglycol, purified water - conservatives:
             METHYL PARAHYDROXYBENZOATE, PROPYL PARAHYDROXYBENZOATE)

          -  Contra-indication to Pomade M.O Cochon® (Known allergy to any components)

          -  Known hypersensitivity to Blenderm®

          -  Extra plantar concomitant warts (to exclude risk of endogenous recontamination by an
             extra plantar site)

          -  Plantar hyperhidrosis making impossible adhesion of plaster.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Aubin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Foot Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

